Literature DB >> 22738394

Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia.

Jane A Freeman1, Kyle R Crassini, O Giles Best, Cecily J Forsyth, Naomi J Mackinlay, Ping Han, William Stevenson, Stephen P Mulligan.   

Abstract

Hypogammaglobulinemia is a common complication of chronic lymphocytic leukemia (CLL), but the significance of immunoglobulin G (IgG) subclass deficiency is unknown. We analyzed the prevalence of immunoglobulins G, A and M, IgG subclass deficiency and infection in 150 patients with CLL. Low IgG, IgA and IgM levels were observed in 27.3%, 30.7% and 56.7% of patients, respectively. IgG subclass deficiency was frequent, with reduced IgG1, IgG2, IgG3 and IgG4 in 28%, 19.3%, 52% and 22.7% of patients, respectively. IgG subclass deficiency (total 64.6%) and hypogammaglobulinemia (27.3%) were more prevalent than clinically significant infection (16%). Recurrent or significant infections were seen in 24 patients (16%), of whom 50% had hypogammaglobulinemia but 100% had at least one IgG subclass deficiency, indicating that half the patients with infection had IgG subclass deficiency but normal total IgG level. Deficiencies of IgG3 and IgG4 were statistically associated with infection risk. Normal immunoglobulin and IgG subclass levels were seen in 26 patients (17%) and none had infections. IgG subclass deficiency is commonly observed in patients with CLL with both normal and reduced total IgG levels, and is associated with infection. Screening patients with CLL for IgG subclass deficiency may be a useful adjunct in stratifying their infection risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22738394     DOI: 10.3109/10428194.2012.706285

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  30 in total

1.  Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy.

Authors:  Andrea Visentin; Nicolò Compagno; Francesco Cinetto; Silvia Imbergamo; Renato Zambello; Francesco Piazza; Gianpietro Semenzato; Livio Trentin; Carlo Agostini
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

2.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Authors:  Sameer A Parikh; Jose F Leis; Kari G Chaffee; Timothy G Call; Curtis A Hanson; Wei Ding; Asher A Chanan-Khan; Deborah Bowen; Michael Conte; Susan Schwager; Susan L Slager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

3.  IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.

Authors:  Ganchimeg Ishdorj; Erin Streu; Pascal Lambert; Harbhajan S Dhaliwal; Salaheddin M Mahmud; Spencer B Gibson; Versha Banerji; Aaron J Marshall; James B Johnston
Journal:  Blood Adv       Date:  2019-07-23

4.  Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy.

Authors:  Serhat Çelik; Leylagül Kaynar; Zeynep Tuğba Güven; Mustafa Baydar; Muzaffer Keklik; Mustafa Çetin; Ali Ünal; Fatih Demirkan
Journal:  Indian J Hematol Blood Transfus       Date:  2021-07-03       Impact factor: 0.900

5.  Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccination.

Authors:  Hye Kyung Lee; Manuela A Hoechstetter; Maike Buchner; Trang Thu Pham; Jin Won Huh; Katharina Müller; Sabine Zange; Heiner von Buttlar; Philipp Girl; Roman Wölfel; Lisa Brandmeier; Lisa Pfeuffer; Priscilla A Furth; Clemens-Martin Wendtner; Lothar Hennighausen
Journal:  medRxiv       Date:  2022-09-21

6.  Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients.

Authors:  Namrata Singh; Sarah L Mott; Grerk Sutamtewagul; Ashley McCarthy; Susan L Slager; James R Cerhan; Zuhair Ballas; Brian K Link
Journal:  EJHaem       Date:  2020-09-01

7.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Clare Sun; Xin Tian; Yuh Shan Lee; Sreenivasulu Gunti; Andrew Lipsky; Sarah E M Herman; Dalia Salem; Maryalice Stetler-Stevenson; Constance Yuan; Lela Kardava; Susan Moir; Irina Maric; Janet Valdez; Susan Soto; Gerald E Marti; Mohammed Z Farooqui; Abner L Notkins; Adrian Wiestner; Georg Aue
Journal:  Blood       Date:  2015-09-03       Impact factor: 22.113

8.  The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).

Authors:  Jennifer A Whitaker; Sameer A Parikh; Tait D Shanafelt; Neil E Kay; Richard B Kennedy; Diane E Grill; Krista M Goergen; Timothy G Call; Saad S Kendarian; Wei Ding; Gregory A Poland
Journal:  Vaccine       Date:  2021-01-16       Impact factor: 3.641

9.  Secondary Hemophagocytic Syndrome Associated with Richter's Transformation in Chronic Lymphocytic Leukemia.

Authors:  Nura El-Haj; Wilson I Gonsalves; Vinay Gupta; Jacob P Smeltzer; Sameer A Parikh; Preet P Singh; Naseema Gangat
Journal:  Case Rep Hematol       Date:  2014-01-16

Review 10.  Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

Authors:  Clare Sun; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.